Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta’s Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley’s novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.)
BPL-003 is a synthetic and patent-protected benzoate salt formulation of 5-MeO-DMT (aka mebufotenin) designed for intranasal administration. The open-label study assessed safety, tolerability and efficacy of the compound at a single 10mg dose, alongside psychological support, in patients with moderate-to-severe TRD (who withdrew from concomitant antidepressants.) Learn more.
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Providers at Utah’s two largest healthcare systems may now treat patients with psilocybin and MDMA as part of a pilot program created by a proposal-turned-law that will take effect as early as May 1, 2024.
The program, open to providers at the University of Utah Health and Intermountain Health, will last three years. Next, the Legislature will decide whether or not to resume it. Learn more.
Elon Musk On Ketamine And Investors’ Value: ‘If There Is Something I’m Taking, I Should Keep Taking It’
Elon Musk once again made the case for using psychedelics. In a new interview with former CNN anchor Don Lemon, the business magnate said prescription ketamine has helped him with occasional depressive episodes. He also suggested that taking the ketamine has also been beneficial for investors in his companies.
The Tesla (NASDAQ:TSLA) and SpaceX chief executive says he takes “a small amount once every other week,” and sometimes less frequently, to treat the “chemical tides” that can trigger his depression. “Ketamine is helpful for getting one out of a negative …